Showing 5751-5760 of 7115 results for "".
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- Tapinarof Improves Plaque Psoriasis in Phase 3 Trialshttps://practicaldermatology.com/news/tapinarof-improves-plaque-psoriasis-in-phase-3-trials/2461004/Tapinarof performed well in two Phase 3 plaque psoriasis trials, according to research published in the New England Journal of Medicine. “This study report
- Derms Give Back: Destination Healthy Skin Wraps Up Its 2021 Journeyhttps://practicaldermatology.com/news/derms-give-back-destination-healthy-skin-wraps-up-its-2021-journey/2461003/Destination Healthy Skin, The Skin Cancer Foundation’s mobile skin cancer education and screening program, conducted 920 free skin cancer screenings aboard the Foundation’s 38-foot Destination Healthy Skin RV. Approximately 4,000 participants attend
- Cosmetic Surgery Forum Kicks Off in Nashvillehttps://practicaldermatology.com/news/cosmetic-surgery-forum-kicks-off-in-nashville/2461001/The no-nonsense presentations and candid audience contributions are center stage in Nashville as Cosmetic Surgery Forum kicks off with a live meeting after a hiatus last year, due to COVID-19 concerns. “We are ready to educate, inform, and have great discussions about topics that
- FDA Clears New Lifting Indications for Sofwavehttps://practicaldermatology.com/news/new-indications-for-sofwave/2460996/Sofwave is now U.S. Food and Drug Administration (FDA)-cleared for lifting the eyebrow and lifting lax submental tissue and neck tissue in people aged 22 or older. In addition, the Sofwave system featuring the Company's proprietary Superb TM (Synchronous Ultrasound Parallel Be
- BTL Launches Scholarship Program with Professional Basketball Player Andre Drummondhttps://practicaldermatology.com/news/btl-launches-scholarship-program-with-professional-basketball-player-andre-drummond/2460991/The BTL SCHOLAR DRAFT will grant five student athletes $15,000 each toward their college tuition. In addition, BTL has partnered with renowned, professional basketball player Andre Drummond to promote the BTL SCHOLAR DRAFT and award the winners. The program officially ki
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Almirall US Supports The Skin Cancer Foundation’s Mobile Skin Cancer Screening Programhttps://practicaldermatology.com/news/almirall-us-supports-the-skin-cancer-foundations-mobile-skin-cancer-screening-program/2460983/Almirall US is supporting The Skin Cancer Foundation’s mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the US, where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms ab
- Nearly One Third of Lupus Patients Show Low Responses to COVID-19 Vaccineshttps://practicaldermatology.com/news/nearly-one-third-of-lupus-patients-show-low-responses-to-covid-19-vaccines/2460980/Nearly 30 percent of lupus patients with had a low response to the new COVID-19 vaccines, finds research presented at ACR Convergence, the American College of Rheumatology’s annual meeting. Since Phase III clinical trials of COVID-19 vaccines excluded people who take im